Temporal pharmacokinetic/pharmacodynamic interaction between human CD3ε antigen-targeted monoclonal antibody otelixizumab and CD3ε binding and expression in human peripheral blood mononuclear cell static culture

The Journal of Pharmacology and Experimental Therapeutics
Kevin R PageAndre van Maurik

Abstract

Otelixizumab is a monoclonal antibody (mAb) directed to human CD3ε, a protein forming part of the CD3/T-cell receptor (TCR) complex on T lymphocytes. This study investigated the temporal interaction between varying concentrations of otelixizumab, binding to human CD3 antigen, and expression of CD3/TCR complexes on lymphocytes in vitro, free from the confounding influence of changing lymphocyte frequencies observed in vivo. A static in vitro culture system was established in which primary human peripheral blood mononuclear cells (PBMCs) were incubated over an extended time course with titrated concentrations of otelixizumab. At each time point, free, bound, and total CD3/TCR expression on both CD4+ and CD8+ T cells and the amount of free otelixizumab antibody in the supernatant were measured. The pharmacokinetics of free otelixizumab in the culture supernatants was saturable, with a shorter apparent half-life at low concentration. Correspondingly, a rapid, otelixizumab concentration-, and time-dependent reduction in CD3/TCR expression was observed. These combined observations were consistent with the phenomenon known as target-mediated drug disposition (TMDD). A mechanistic, mathematical pharmacokinetic/pharmacodynamic (PK/PD) m...Continue Reading

References

Nov 1, 1991·European Journal of Immunology·E G RoutledgeH Waldmann
Jul 1, 1991·Neurology·B G WeinshenkerG P Rice
Nov 1, 1982·European Journal of Immunology·L ChatenoudJ F Bach
Sep 1, 1994·Clinical Pharmacology and Therapeutics·G Levy
Apr 21, 1997·The Journal of Experimental Medicine·J A SmithJ A Bluestone
Feb 22, 2002·European Journal of Immunology·Charlotte MennéCarsten Geisler
May 10, 2002·Journal of Pharmacokinetics and Pharmacodynamics·D E Mager, W J Jusko
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Jun 24, 2004·Computer Methods and Programs in Biomedicine·Lars LindbomE Niclas Jonsson
Nov 2, 2004·The Journal of Biological Chemistry·Alicia MonjasBalbino Alarcón
Jun 24, 2005·The New England Journal of Medicine·Bart KeymeulenLucienne Chatenoud
Nov 28, 2006·European Journal of Immunology·Adriana CaballeroJames R Drake
Mar 31, 2009·Analytical Chemistry·Charles CougnonJanine Mauzeroll
Jul 30, 2010·Journal of Pharmacokinetics and Pharmacodynamics·Leonid Gibiansky, Ekaterina Gibiansky
Feb 4, 2011·Science Translational Medicine·Chantal KuhnLucienne Chatenoud
Jan 27, 2012·Science Translational Medicine·Frank Waldron-LynchKevan C Herold
Sep 12, 2014·Pharmaceutical Research·Inna VainshteinMeina Liang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.